Literature DB >> 30366115

Ovarian Reserve and Assisted Reproductive Technique Outcomes After Laparoscopic Proximal Tubal Occlusion or Salpingectomy in Women with Hydrosalpinx Undergoing in Vitro Fertilization: A Randomized Controlled Trial.

Chithira Pulimoottil Vignarajan1, Neena Malhotra2, Neeta Singh1.   

Abstract

STUDY
OBJECTIVE: To evaluate the outcomes of assisted reproductive technology (ART) after proximal tubal occlusion (PTO) or salpingectomy in patients with hydrosalpinx undergoing in vitro fertilization-embryo transfer (IVF-ET).
DESIGN: Randomized controlled trial (Canadian Task Force classification I).
SETTING: All India Institute of Medical Sciences, New Delhi, India. PATIENTS: A total of 165 patients were randomized and subsequently allocated to a PTO group (n = 83) or a salpingectomy group (n = 82).
INTERVENTIONS: PTO and salpingectomy.
MEASUREMENTS AND MAIN RESULTS: Following surgery, compared with the PTO group, the salpingectomy group showed significant decreases in the ovarian reserve parameters serum anti-Müllerian hormone (AMH; 3.7 ng/mL vs 2.6 ng/mL; p ˂ .001) and antral follicle count (AFC; 10.6 vs 8.6; p ˂ .001). The salpingectomy group also required a significantly higher dose of gonadotropins (3901 vs 3260; p ˂ .001) and more days of stimulation (11.3 vs 10.2; p ˂ .001) compared with the PTO group. The salpingectomy group had a significantly lower fertilization rate (0.74 vs 0.83; p ˂ .001) and a lower number of grade 1 embryos (4.1 vs 5.6; p = .02); however, there was no significant difference between the 2 groups with respect to rates of implantation (22.8% vs 23.7%; p = .87), clinical pregnancy (26.3% vs 33.7%, p = .25), live birth (27.5% vs 32.5%; p = .42), and miscarriage (4.7% vs 3.5%; p = .90)
CONCLUSIONS: PTO is a superior to salpingectomy for the surgical management of patients with hydrosalpinx undergoing IVF-ET in terms of ovarian reserve. However, the 2 surgical techniques are associated with comparable pregnancy rates.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  Hydrosalpinx; Proximal tubal occlusion; Salpingectomy

Mesh:

Year:  2018        PMID: 30366115     DOI: 10.1016/j.jmig.2018.10.013

Source DB:  PubMed          Journal:  J Minim Invasive Gynecol        ISSN: 1553-4650            Impact factor:   4.137


  6 in total

1.  Ovarian Response, Pregnancy Outcomes, and Complications Between Salpingectomy and Proximal Tubal Occlusion in Hydrosalpinx Patients Before in vitro Fertilization: A Meta-Analysis.

Authors:  Hua Ou; Jie Sun; Lin Lin; Xiao Ma
Journal:  Front Surg       Date:  2022-04-29

2.  Prior salpingectomy impairs the retrieved oocyte number in in vitro fertilization cycles of women under 35 years old without optimal ovarian reserve.

Authors:  Cheng-Yu Ho; Yu-Yuan Chang; Yu-Hung Lin; Mei-Jou Chen
Journal:  PLoS One       Date:  2022-05-04       Impact factor: 3.240

3.  Surgical treatment for tubal disease in women due to undergo in vitro fertilisation.

Authors:  Pedro Melo; Ektoras X Georgiou; Neil Johnson; Sabine F van Voorst; Annika Strandell; Ben Willem J Mol; Christian Becker; Ingrid E Granne
Journal:  Cochrane Database Syst Rev       Date:  2020-10-22

4.  Comparison of the efficacy between bilateral proximal tubal occlusion and total salpingectomy on ovarian reserve and the cholinergic system: an experimental study

Authors:  Remzi Atilgan; Şehmus Pala; Tuncay Kuloğlu; Cengiz Şanli; Şeyda Yavuzkir; Zehra Sema Özkan
Journal:  Turk J Med Sci       Date:  2020-06-23       Impact factor: 0.973

5.  Knowledge of iatrogenic premature ovarian insufficiency among Chinese obstetricians and gynaecologists: a national questionnaire survey.

Authors:  Yanfang Wang; Ying Zou; Wei Wang; Qingmei Zheng; Ying Feng; Han Dong; Zhangyun Tan; Xiaoqin Zeng; Yinqing Zhao; Danhong Peng; Xiaomin Yang; Aijun Sun
Journal:  J Ovarian Res       Date:  2020-11-18       Impact factor: 4.234

6.  Effect comparison of salpingectomy versus proximal tubal occlusion on ovarian reserve: A meta-analysis.

Authors:  Shuxie Wu; Qiong Zhang; Yanping Li
Journal:  Medicine (Baltimore)       Date:  2020-07-24       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.